Keywords: Cancer, Cancer, Rectal cancer; Neoadjuvant chemotherapy; Complete response; Magnetic resonance tumor regression grade; Diffusion-weighted imaging.
Motivation: The role of MRI in evaluating the tumor response following neoadjuvant chemotherapy (NCT) in rectal cancers remains pending.
Goal(s): To investigate the reliability of MRI in assessing the pathological clinical response (pCR) in rectal cancer patients with NCT.
Approach: In two consecutive prospective clinical trials (Clinicaltrials.gov NCT03666442 and NCT04922853), tumor responses to NCT were evaluated using MRI-based models.
Results: 224 patients were enrolled. MR-TRG, DWI, DWImodMR-TRG mriCR, and rNAR score were all associated with pCR. DWImodMR-TRG achieved the highest area under the curve (AUC) of 0.940, with the highest sensitivity of 0.905 and the highest PPV of 0.976.
Impact: MRI-based models were feasible in determining the tumor response in LARC patients following NCT. DWI may improve the predictive performance of MR-TRG. Our findings provide evidence for the determination of tumor response for rectal cancer patients who underwent NCT.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords